Home / Centerstage / 2015 / May / Week 1 /
Alexion Pharmaceuticals agrees to acquire Synageva BioPharma, a company specializing in rare disease treatments, for $8.6 billion. This strategic acquisition enhances Alexion's portfolio in the field of rare diseases, allowing them to provide innovative medicines to patients with high unmet medical needs. Synageva BioPharma brings valuable expertise and a pipeline of potential therapies to address these rare conditions.
Tuesday, 5 May, 2015